Leadership
Dr. Zadno has served as PROCEPT BioRobotics President and Chief Executive Officer and a member of the board of directors since February 2020. Prior to joining PROCEPT BioRobotics Dr. Zadno served as President and Chief Executive Officer of Avedro, Inc., an ophthalmology company that developed a proprietary Corneal Remodeling Platform Technology. During his time at Avedro, Inc. from September 2016 to November 2020, he led the company through an IPO and rapid commercialization, and ultimately an acquisition by Glaukos; he also served as a member of the board of directors at Avedro. Prior to Avedro, Dr. Zadno served as Innovation Advisor and Venture Partner at InterWest Partners, a venture capital firm, from January 2012 to January 2018. Dr. Zadno has also served on the boards of directors of Invuity, Inc. from January 2013 to June 2017, where he was a member of the audit committee, and Carbylan Therapeutics, Inc. from June 2013 to November 2016, where he was a member of the audit committee. Dr. Zadno also served on the Board of a number of additional private companies. Dr. Zadno also co-founded PercuSurge, a maker of distal protection devices used in treating occluded carotid arteries and saphenous vein grafts, which was acquired by Medtronic. Dr. Zadno received both a Ph.D. and an M.Sc. in Mechanical Properties of Materials from École Nationale Supérieure des Mines de Paris.
Mr. Waters has served as PROCEPT BioRobotics SVP, Chief Financial Officer since October 2018. Prior to joining PROCEPT BioRobotics Mr. Waters served as Chief Financial Officer at Accuray Inc., a radiation oncology company, from September 2015 to October 2018. In addition to his experience at Accuray, Inc., Mr. Waters held financial leadership positions at three publicly traded medical device companies, including Conceptus, Laserscope and VISX. These companies were all sold to strategic acquirers, generating approximately $3 billion in shareholder value. Mr. Waters began his career at PricewaterhouseCoopers, LLP. and received a B.S. in Business Administration, with a double concentration in Accounting and Finance from Cal Poly San Luis Obispo.
Mr. Shiblaq has served as PROCEPT BioRobotics SVP, Global Commercialization since March 2019. Prior to joining PROCEPT BioRobotics, Mr. Shiblaq served as Vice President of Commercial Operations at Invuity, Inc., the leader in advanced photonics and single-use, lighted instruments, until its acquisition by Stryker from January 2017 to January 2019. Prior to Invuity, Mr. Shiblaq served as Vice President of Sales at Analogic Corporation from June 2016 to January 2017. Mr. Shiblaq also held sales and commercial leadership positions at Intuitive Surgical, where he was responsible for driving the growth of emerging procedures in General, Thoracic and Gynecologic Surgery. Prior to Intuitive Surgical, Mr. Shiblaq held various Commercial leadership positions at Conceptus Inc., until its acquisition by Bayer AG. Mr. Shiblaq received a B.A. in Psychology from Ohio State University.
Ms. Nouri has served as PROCEPT BioRobotics SVP, General Counsel & Corporate Secretary since July 2018. Prior to joining PROCEPT BioRobotics, Ms. Nouri served as Senior Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer at Accuray Inc., a radiation oncology company, from February 2014 to July 2018. In her more than 15-year legal career in private practice law firms and with corporations as in-house counsel, Ms. Nouri has advised on corporate, transactional, and regulatory compliance matters including corporate governance, strategic transactions, mergers and acquisitions, intellectual property portfolio management, public disclosure issues, and SEC reporting and compliance. Ms. Nouri received a J.D. from U.C. Hastings College of Law and a Bachelor of Commerce in International Business and also completed the requirements for a finance specialization from the University of British Columbia.
Mr. Chandran brings 20 years of combined experience in quality assurance, regulatory affairs, test engineering, and program management. He has a passion for bringing new and disruptive technologies to market by building compliant yet flexible RAQA infrastructure based on product and business for both US and Int’l markets. Mr. Chandran has held quality and regulatory leadership positions at numerous medical device companies, including Stryker Endoscopy, Siemens Ultrasound, Arthrocare Corporation (Smith & Nephew), InSound Medical (Phonak), myoscience & R2 Dermatology. He has a BE in Electronics and Communications Engineering from India and has an MS in Electrical Engineering from University of Texas at Austin and is also a Stanford Certified Project Manager (SCPM).
Mr. Salkeld has 20 years medical device industry experience in Sales and Sales Management, Strategy and Product Marketing, Clinical Market Development, and Finance. Prior to PROCEPT, Mr. Salkeld spent 7 years at Acclarent, acquired by Johnson & Johnson in 2010 where he was a member of the executive team with responsibilities including US Sales, WW Marketing, & Professional Education. Previous roles included extensive experience in the cardiovascular area with executive Sales & Marketing positions at Cierra, Inc. and Vascular Architects, as well as a variety of roles at Guidant, which was acquired by Abbott Vascular. Prior to Guidant, Mr. Salkeld was a Manager at Ernst & Young, LLP. Mr. Salkeld holds a BS in Commerce and an MBA from Santa Clara University.
Mr. Sancheti has been in operations leadership positions for over 15 years and has over 30 years of manufacturing, supply chain, engineering and operations experience in medical devices including vascular implants, catheters, RF ablation, respiratory assist devices and Robotic Assisted Surgery. Prior to joining PROCEPT BioRobotics, he served as VP, Manufacturing Operations at Intuitive Surgical, among other leadership positions he held there. Previously, Mr. Sancheti held VP Operations roles at Altura Medical, Ceterix Orthopedics, Breathe Technologies and VNUS Medical Technologies. He holds a Bachelor of Science in Mechanical Engineering from the Birla Institute of Technology and Science in India, and a Master of Science in Manufacturing Engineering from the University of Massachusetts.
Mr. Templin has over 15 years of experience in clinical research, engineering, and market development, primarily within the medical device industry. Most recently, he served as the VP of Clinical Research, Engineering, and Therapy Development for CardioKinetix. Prior to CardioKinetix, Mr. Templin was the Global Clinical Program Director for Abbott Vascular. He also led the landmark vulnerable plaque natural history study, PROSPECT. Prior to that role, Mr. Templin held engineering roles with GE Aircraft Engines and Guidant, and then clinical positions with Guidant (that was later acquired by Abbott). Mr. Templin holds a BS in Mechanical Engineering and minor in Economics from Rose-Hulman Institute of Technology and an MBA from Duke.
Ms. Vittal has 20 years of experience in People, Culture and Engagement with a career spanning medical device, fin-tech and high-tech industries. Prior to joining PROCEPT BioRobotics, she was VP, HR at Varian Medical Systems, a world leader in radiotherapy and cancer care, and previously held HR leadership roles at PayPal and CA Technologies. She has experience in building business-driven people programs and high-performing cultures in rapid change environments and has led initiatives in HR business partnership, talent management, organization development and total rewards. Ms. Vittal has a Bachelor of Arts (Honors) degree in Economics from Delhi University, India and a Master of Business Administration from Management Development Institute, Gurgaon, India.
Dr. Zadno has served as PROCEPT BioRobotics President and Chief Executive Officer and a member of the board of directors since February 2020. Prior to joining PROCEPT BioRobotics Dr. Zadno served as President and Chief Executive Officer of Avedro, Inc., an ophthalmology company that developed a proprietary Corneal Remodeling Platform Technology. During his time at Avedro, Inc. from September 2016 to November 2020, he led the company through an IPO and rapid commercialization, and ultimately an acquisition by Glaukos; he also served as a member of the board of directors at Avedro. Prior to Avedro, Dr. Zadno served as Innovation Advisor and Venture Partner at InterWest Partners, a venture capital firm, from January 2012 to January 2018. Dr. Zadno has also served on the boards of directors of Invuity, Inc. from January 2013 to June 2017, where he was a member of the audit committee, and Carbylan Therapeutics, Inc. from June 2013 to November 2016, where he was a member of the audit committee. Dr. Zadno also served on the Board of a number of additional private companies. Dr. Zadno also co-founded PercuSurge, a maker of distal protection devices used in treating occluded carotid arteries and saphenous vein grafts, which was acquired by Medtronic. Dr. Zadno received both a Ph.D. and an M.Sc. in Mechanical Properties of Materials from École Nationale Supérieure des Mines de Paris.
Mr. Waters has served as PROCEPT BioRobotics SVP, Chief Financial Officer since October 2018. Prior to joining PROCEPT BioRobotics Mr. Waters served as Chief Financial Officer at Accuray Inc., a radiation oncology company, from September 2015 to October 2018. In addition to his experience at Accuray, Inc., Mr. Waters held financial leadership positions at three publicly traded medical device companies, including Conceptus, Laserscope and VISX. These companies were all sold to strategic acquirers, generating approximately $3 billion in shareholder value. Mr. Waters began his career at PricewaterhouseCoopers, LLP. and received a B.S. in Business Administration, with a double concentration in Accounting and Finance from Cal Poly San Luis Obispo.
Mr. Shiblaq has served as PROCEPT BioRobotics SVP, Global Commercialization since March 2019. Prior to joining PROCEPT BioRobotics, Mr. Shiblaq served as Vice President of Commercial Operations at Invuity, Inc., the leader in advanced photonics and single-use, lighted instruments, until its acquisition by Stryker from January 2017 to January 2019. Prior to Invuity, Mr. Shiblaq served as Vice President of Sales at Analogic Corporation from June 2016 to January 2017. Mr. Shiblaq also held sales and commercial leadership positions at Intuitive Surgical, where he was responsible for driving the growth of emerging procedures in General, Thoracic and Gynecologic Surgery. Prior to Intuitive Surgical, Mr. Shiblaq held various Commercial leadership positions at Conceptus Inc., until its acquisition by Bayer AG. Mr. Shiblaq received a B.A. in Psychology from Ohio State University.
Ms. Nouri has served as PROCEPT BioRobotics SVP, General Counsel & Corporate Secretary since July 2018. Prior to joining PROCEPT BioRobotics, Ms. Nouri served as Senior Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer at Accuray Inc., a radiation oncology company, from February 2014 to July 2018. In her more than 15-year legal career in private practice law firms and with corporations as in-house counsel, Ms. Nouri has advised on corporate, transactional, and regulatory compliance matters including corporate governance, strategic transactions, mergers and acquisitions, intellectual property portfolio management, public disclosure issues, and SEC reporting and compliance. Ms. Nouri received a J.D. from U.C. Hastings College of Law and a Bachelor of Commerce in International Business and also completed the requirements for a finance specialization from the University of British Columbia.
Mr. Chandran brings 20 years of combined experience in quality assurance, regulatory affairs, test engineering, and program management. He has a passion for bringing new and disruptive technologies to market by building compliant yet flexible RAQA infrastructure based on product and business for both US and Int’l markets. Mr. Chandran has held quality and regulatory leadership positions at numerous medical device companies, including Stryker Endoscopy, Siemens Ultrasound, Arthrocare Corporation (Smith & Nephew), InSound Medical (Phonak), myoscience & R2 Dermatology. He has a BE in Electronics and Communications Engineering from India and has an MS in Electrical Engineering from University of Texas at Austin and is also a Stanford Certified Project Manager (SCPM).
Mr. Salkeld has 20 years medical device industry experience in Sales and Sales Management, Strategy and Product Marketing, Clinical Market Development, and Finance. Prior to PROCEPT, Mr. Salkeld spent 7 years at Acclarent, acquired by Johnson & Johnson in 2010 where he was a member of the executive team with responsibilities including US Sales, WW Marketing, & Professional Education. Previous roles included extensive experience in the cardiovascular area with executive Sales & Marketing positions at Cierra, Inc. and Vascular Architects, as well as a variety of roles at Guidant, which was acquired by Abbott Vascular. Prior to Guidant, Mr. Salkeld was a Manager at Ernst & Young, LLP. Mr. Salkeld holds a BS in Commerce and an MBA from Santa Clara University.
Mr. Sancheti has been in operations leadership positions for over 15 years and has over 30 years of manufacturing, supply chain, engineering and operations experience in medical devices including vascular implants, catheters, RF ablation, respiratory assist devices and Robotic Assisted Surgery. Prior to joining PROCEPT BioRobotics, he served as VP, Manufacturing Operations at Intuitive Surgical, among other leadership positions he held there. Previously, Mr. Sancheti held VP Operations roles at Altura Medical, Ceterix Orthopedics, Breathe Technologies and VNUS Medical Technologies. He holds a Bachelor of Science in Mechanical Engineering from the Birla Institute of Technology and Science in India, and a Master of Science in Manufacturing Engineering from the University of Massachusetts.
Mr. Templin has over 15 years of experience in clinical research, engineering, and market development, primarily within the medical device industry. Most recently, he served as the VP of Clinical Research, Engineering, and Therapy Development for CardioKinetix. Prior to CardioKinetix, Mr. Templin was the Global Clinical Program Director for Abbott Vascular. He also led the landmark vulnerable plaque natural history study, PROSPECT. Prior to that role, Mr. Templin held engineering roles with GE Aircraft Engines and Guidant, and then clinical positions with Guidant (that was later acquired by Abbott). Mr. Templin holds a BS in Mechanical Engineering and minor in Economics from Rose-Hulman Institute of Technology and an MBA from Duke.
Ms. Vittal has 20 years of experience in People, Culture and Engagement with a career spanning medical device, fin-tech and high-tech industries. Prior to joining PROCEPT BioRobotics, she was VP, HR at Varian Medical Systems, a world leader in radiotherapy and cancer care, and previously held HR leadership roles at PayPal and CA Technologies. She has experience in building business-driven people programs and high-performing cultures in rapid change environments and has led initiatives in HR business partnership, talent management, organization development and total rewards. Ms. Vittal has a Bachelor of Arts (Honors) degree in Economics from Delhi University, India and a Master of Business Administration from Management Development Institute, Gurgaon, India.
Dr. Zadno has served as PROCEPT BioRobotics President and Chief Executive Officer and a member of the board of directors since February 2020. Prior to joining PROCEPT BioRobotics Dr. Zadno served as President and Chief Executive Officer of Avedro, Inc., an ophthalmology company that developed a proprietary Corneal Remodeling Platform Technology. During his time at Avedro, Inc. from September 2016 to November 2020, he led the company through an IPO and rapid commercialization, and ultimately an acquisition by Glaukos; he also served as a member of the board of directors at Avedro. Prior to Avedro, Dr. Zadno served as Innovation Advisor and Venture Partner at InterWest Partners, a venture capital firm, from January 2012 to January 2018. Dr. Zadno has also served on the boards of directors of Invuity, Inc. from January 2013 to June 2017, where he was a member of the audit committee, and Carbylan Therapeutics, Inc. from June 2013 to November 2016, where he was a member of the audit committee. Dr. Zadno also served on the Board of a number of additional private companies. Dr. Zadno also co-founded PercuSurge, a maker of distal protection devices used in treating occluded carotid arteries and saphenous vein grafts, which was acquired by Medtronic. Dr. Zadno received both a Ph.D. and an M.Sc. in Mechanical Properties of Materials from École Nationale Supérieure des Mines de Paris.
Dr. Moll is the founder, Chairman and CEO of Auris Surgical Robotics. Prior to Auris he was co-founder of Hansen Medical, Restoration Robotics and founder and first CEO of Intuitive Surgical, the world leader in surgical robotics, and a major player in urology. Dr. Moll was a co-founder of Origin Medsystems, and served as the Medical Director of Guidant's Surgical Device Division. Early in his career he founded Endotherapeutics, a pioneering company in laparoscopic surgical technology.
Dr. Moll holds a B.A. degree from the University of California at Berkeley, an M.S. degree in management from Stanford University, and an M.D. degree from the University of Washington.
Dr. Perkins is an internationally known ear surgeon, the founder of the California Ear Institute at Stanford and a successful serial medical device entrepreneur. He is the founder of three public companies: Collagen, Laserscope, and ReSound, and was chairman of the latter two. Dr. Perkins is or was founder or co-founder and chairman of Cohesion, Novacept, Pulmonx, Sound ID, Surgrx, Define, Minerva, Iogyn and Soundhawk.
Dr. Perkins received the Phoenix Hall of Fame Innovation Award and the Lifetime Achievement Award from Medical Futures, a British organization that fosters innovation in medicine. He is a graduate of the Indiana University School of Medicine where he recently received the Distinguished Medical Alumnus Award. Dr. Perkins is a Clinical Professor of Surgery at Stanford and holds over 40 patents.
Mr. Desai is a partner at CPMG, Inc. CPMG is an investment firm that employs a concentrated, value-oriented approach to investing in publicly traded and private operating companies. Prior to joining CPMG’s predecessor, Cardinal Investment Company, Mr. Desai worked as an analyst at WhiteHorse Capital Partners, L.P. He currently serves on the Board of Directors of PROCEPT BioRobotics Corporation, Theatro Labs, Inc., ESN Venture Holdings LLC, Lifeblue Incorporated, and Travel Research Advisors LLC. Mr. Desai holds a B.S. and an M.B.A. from The Wharton School at the University of Pennsylvania.
Ms. Dodrill has served healthcare and technology companies for more than 20 years and is currently the President of Global Surgical Solutions at Hillrom Holdings, Inc. ("Hillrom"). At Hillrom, she has been responsible for achieving enhanced operational effectiveness, market expansion and market share growth. Prior roles at Hillrom include Vice President and General Manager, US Surgical Division, Vice President and General Manager of Trumpf Medical Surgical Solutions NA and Area Vice President & General Manager. Earlier in her career, she served as a Vice President, Commercial Operations at DynaVox, and prior to that was a Regional Vice President at GE Healthcare. Ms. Dodrill holds a Bachelor of Science in Biomedical Engineering from Johns Hopkins University and completed a fellowship in Physiology at Wake Forest University.
Mr. Wood is a Portfolio Manager and Research Analyst for Oechsle International Advisors in London where he is responsible for medical technology investments globally. Prior to this current position, he was with Freeman & Company, a boutique M&A advisory firm focused on the financial services industry. Earlier in his career Mr. Wood was actively involved as an investor, asset gatherer and business development executive for early stage companies in financial services and medical technology sectors.
Mr. Wood holds a B.A. from the University of Delaware and an MBA in Finance and Entrepreneurship from the F.W. Olin Graduate of Business at Babson College.
Mr. Harris most recently served as the Chief Financial Officer of MyoKardia, Inc., a clinical-stage biopharmaceutical company discovering and developing therapies for the treatment of serious cardiovascular diseases. MyoKardia was acquired in November 2020 by Bristol Myers Squibb for $13.1 billion. Prior to joining MyoKardia, Mr. Harris served as Chief Financial Officer of Zeltiq Aesthetics, Inc., until that company’s acquisition by Allergan plc. Prior to Zeltiq, Mr. Harris served as Chief Financial Officer at Thoratec Corporation, until that company’s acquisition by St. Jude Medical, Inc. Prior to joining Thoratec, Mr. Harris worked at JPMorgan Chase & Co. for over a decade in several capacities, including as a Vice President in the firm's Healthcare Investment Banking and Equity Research departments. Mr. Harris holds a Bachelor of Arts in Physics and Economics from the University of North Carolina at Chapel Hill, where he studied as a Morehead-Cain Scholar.
Dr. Krummel is the Surgeon-in-Chief at Lucile Packard Children’s Hospital and Chairman of the Surgery Department at the Stanford University School of Medicine, He is the founder of the Surgical Innovation Program at Stanford, and Co-Director of the Stanford Biodesign Program which teaches innovation and implementation of new surgical technologies. The program has spawned 35 start-ups which have received more than $300 million in follow-on financing.
Dr. Krummel has lectured throughout the world and is author or co-author of over 300 publications, chapters, abstracts and books. He is on the board of the Fogarty Innovation Institute and has served on the board of directors or scientific advisory boards of 15 medical device start-ups.
Dr. Zadno has served as PROCEPT BioRobotics President and Chief Executive Officer and a member of the board of directors since February 2020. Prior to joining PROCEPT BioRobotics Dr. Zadno served as President and Chief Executive Officer of Avedro, Inc., an ophthalmology company that developed a proprietary Corneal Remodeling Platform Technology. During his time at Avedro, Inc. from September 2016 to November 2020, he led the company through an IPO and rapid commercialization, and ultimately an acquisition by Glaukos; he also served as a member of the board of directors at Avedro. Prior to Avedro, Dr. Zadno served as Innovation Advisor and Venture Partner at InterWest Partners, a venture capital firm, from January 2012 to January 2018. Dr. Zadno has also served on the boards of directors of Invuity, Inc. from January 2013 to June 2017, where he was a member of the audit committee, and Carbylan Therapeutics, Inc. from June 2013 to November 2016, where he was a member of the audit committee. Dr. Zadno also served on the Board of a number of additional private companies. Dr. Zadno also co-founded PercuSurge, a maker of distal protection devices used in treating occluded carotid arteries and saphenous vein grafts, which was acquired by Medtronic. Dr. Zadno received both a Ph.D. and an M.Sc. in Mechanical Properties of Materials from École Nationale Supérieure des Mines de Paris.
Dr. Moll is the founder, Chairman and CEO of Auris Surgical Robotics. Prior to Auris he was co-founder of Hansen Medical, Restoration Robotics and founder and first CEO of Intuitive Surgical, the world leader in surgical robotics, and a major player in urology. Dr. Moll was a co-founder of Origin Medsystems, and served as the Medical Director of Guidant's Surgical Device Division. Early in his career he founded Endotherapeutics, a pioneering company in laparoscopic surgical technology.
Dr. Moll holds a B.A. degree from the University of California at Berkeley, an M.S. degree in management from Stanford University, and an M.D. degree from the University of Washington.
Dr. Perkins is an internationally known ear surgeon, the founder of the California Ear Institute at Stanford and a successful serial medical device entrepreneur. He is the founder of three public companies: Collagen, Laserscope, and ReSound, and was chairman of the latter two. Dr. Perkins is or was founder or co-founder and chairman of Cohesion, Novacept, Pulmonx, Sound ID, Surgrx, Define, Minerva, Iogyn and Soundhawk.
Dr. Perkins received the Phoenix Hall of Fame Innovation Award and the Lifetime Achievement Award from Medical Futures, a British organization that fosters innovation in medicine. He is a graduate of the Indiana University School of Medicine where he recently received the Distinguished Medical Alumnus Award. Dr. Perkins is a Clinical Professor of Surgery at Stanford and holds over 40 patents.
Mr. Desai is a partner at CPMG, Inc. CPMG is an investment firm that employs a concentrated, value-oriented approach to investing in publicly traded and private operating companies. Prior to joining CPMG’s predecessor, Cardinal Investment Company, Mr. Desai worked as an analyst at WhiteHorse Capital Partners, L.P. He currently serves on the Board of Directors of PROCEPT BioRobotics Corporation, Theatro Labs, Inc., ESN Venture Holdings LLC, Lifeblue Incorporated, and Travel Research Advisors LLC. Mr. Desai holds a B.S. and an M.B.A. from The Wharton School at the University of Pennsylvania.
Ms. Dodrill has served healthcare and technology companies for more than 20 years and is currently the President of Global Surgical Solutions at Hillrom Holdings, Inc. ("Hillrom"). At Hillrom, she has been responsible for achieving enhanced operational effectiveness, market expansion and market share growth. Prior roles at Hillrom include Vice President and General Manager, US Surgical Division, Vice President and General Manager of Trumpf Medical Surgical Solutions NA and Area Vice President & General Manager. Earlier in her career, she served as a Vice President, Commercial Operations at DynaVox, and prior to that was a Regional Vice President at GE Healthcare. Ms. Dodrill holds a Bachelor of Science in Biomedical Engineering from Johns Hopkins University and completed a fellowship in Physiology at Wake Forest University.
Mr. Wood is a Portfolio Manager and Research Analyst for Oechsle International Advisors in London where he is responsible for medical technology investments globally. Prior to this current position, he was with Freeman & Company, a boutique M&A advisory firm focused on the financial services industry. Earlier in his career Mr. Wood was actively involved as an investor, asset gatherer and business development executive for early stage companies in financial services and medical technology sectors.
Mr. Wood holds a B.A. from the University of Delaware and an MBA in Finance and Entrepreneurship from the F.W. Olin Graduate of Business at Babson College.
Mr. Harris most recently served as the Chief Financial Officer of MyoKardia, Inc., a clinical-stage biopharmaceutical company discovering and developing therapies for the treatment of serious cardiovascular diseases. MyoKardia was acquired in November 2020 by Bristol Myers Squibb for $13.1 billion. Prior to joining MyoKardia, Mr. Harris served as Chief Financial Officer of Zeltiq Aesthetics, Inc., until that company’s acquisition by Allergan plc. Prior to Zeltiq, Mr. Harris served as Chief Financial Officer at Thoratec Corporation, until that company’s acquisition by St. Jude Medical, Inc. Prior to joining Thoratec, Mr. Harris worked at JPMorgan Chase & Co. for over a decade in several capacities, including as a Vice President in the firm's Healthcare Investment Banking and Equity Research departments. Mr. Harris holds a Bachelor of Arts in Physics and Economics from the University of North Carolina at Chapel Hill, where he studied as a Morehead-Cain Scholar.
Dr. Krummel is the Surgeon-in-Chief at Lucile Packard Children’s Hospital and Chairman of the Surgery Department at the Stanford University School of Medicine, He is the founder of the Surgical Innovation Program at Stanford, and Co-Director of the Stanford Biodesign Program which teaches innovation and implementation of new surgical technologies. The program has spawned 35 start-ups which have received more than $300 million in follow-on financing.
Dr. Krummel has lectured throughout the world and is author or co-author of over 300 publications, chapters, abstracts and books. He is on the board of the Fogarty Innovation Institute and has served on the board of directors or scientific advisory boards of 15 medical device start-ups.
Dr. Zadno has served as PROCEPT BioRobotics President and Chief Executive Officer and a member of the board of directors since February 2020. Prior to joining PROCEPT BioRobotics Dr. Zadno served as President and Chief Executive Officer of Avedro, Inc., an ophthalmology company that developed a proprietary Corneal Remodeling Platform Technology. During his time at Avedro, Inc. from September 2016 to November 2020, he led the company through an IPO and rapid commercialization, and ultimately an acquisition by Glaukos; he also served as a member of the board of directors at Avedro. Prior to Avedro, Dr. Zadno served as Innovation Advisor and Venture Partner at InterWest Partners, a venture capital firm, from January 2012 to January 2018. Dr. Zadno has also served on the boards of directors of Invuity, Inc. from January 2013 to June 2017, where he was a member of the audit committee, and Carbylan Therapeutics, Inc. from June 2013 to November 2016, where he was a member of the audit committee. Dr. Zadno also served on the Board of a number of additional private companies. Dr. Zadno also co-founded PercuSurge, a maker of distal protection devices used in treating occluded carotid arteries and saphenous vein grafts, which was acquired by Medtronic. Dr. Zadno received both a Ph.D. and an M.Sc. in Mechanical Properties of Materials from École Nationale Supérieure des Mines de Paris.
Mr. Waters has served as PROCEPT BioRobotics SVP, Chief Financial Officer since October 2018. Prior to joining PROCEPT BioRobotics Mr. Waters served as Chief Financial Officer at Accuray Inc., a radiation oncology company, from September 2015 to October 2018. In addition to his experience at Accuray, Inc., Mr. Waters held financial leadership positions at three publicly traded medical device companies, including Conceptus, Laserscope and VISX. These companies were all sold to strategic acquirers, generating approximately $3 billion in shareholder value. Mr. Waters began his career at PricewaterhouseCoopers, LLP. and received a B.S. in Business Administration, with a double concentration in Accounting and Finance from Cal Poly San Luis Obispo.
Mr. Shiblaq has served as PROCEPT BioRobotics SVP, Global Commercialization since March 2019. Prior to joining PROCEPT BioRobotics, Mr. Shiblaq served as Vice President of Commercial Operations at Invuity, Inc., the leader in advanced photonics and single-use, lighted instruments, until its acquisition by Stryker from January 2017 to January 2019. Prior to Invuity, Mr. Shiblaq served as Vice President of Sales at Analogic Corporation from June 2016 to January 2017. Mr. Shiblaq also held sales and commercial leadership positions at Intuitive Surgical, where he was responsible for driving the growth of emerging procedures in General, Thoracic and Gynecologic Surgery. Prior to Intuitive Surgical, Mr. Shiblaq held various Commercial leadership positions at Conceptus Inc., until its acquisition by Bayer AG. Mr. Shiblaq received a B.A. in Psychology from Ohio State University.
Ms. Nouri has served as PROCEPT BioRobotics SVP, General Counsel & Corporate Secretary since July 2018. Prior to joining PROCEPT BioRobotics, Ms. Nouri served as Senior Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer at Accuray Inc., a radiation oncology company, from February 2014 to July 2018. In her more than 15-year legal career in private practice law firms and with corporations as in-house counsel, Ms. Nouri has advised on corporate, transactional, and regulatory compliance matters including corporate governance, strategic transactions, mergers and acquisitions, intellectual property portfolio management, public disclosure issues, and SEC reporting and compliance. Ms. Nouri received a J.D. from U.C. Hastings College of Law and a Bachelor of Commerce in International Business and also completed the requirements for a finance specialization from the University of British Columbia.
Mr. Chandran brings 20 years of combined experience in quality assurance, regulatory affairs, test engineering, and program management. He has a passion for bringing new and disruptive technologies to market by building compliant yet flexible RAQA infrastructure based on product and business for both US and Int’l markets. Mr. Chandran has held quality and regulatory leadership positions at numerous medical device companies, including Stryker Endoscopy, Siemens Ultrasound, Arthrocare Corporation (Smith & Nephew), InSound Medical (Phonak), myoscience & R2 Dermatology. He has a BE in Electronics and Communications Engineering from India and has an MS in Electrical Engineering from University of Texas at Austin and is also a Stanford Certified Project Manager (SCPM).
Mr. Salkeld has 20 years medical device industry experience in Sales and Sales Management, Strategy and Product Marketing, Clinical Market Development, and Finance. Prior to PROCEPT, Mr. Salkeld spent 7 years at Acclarent, acquired by Johnson & Johnson in 2010 where he was a member of the executive team with responsibilities including US Sales, WW Marketing, & Professional Education. Previous roles included extensive experience in the cardiovascular area with executive Sales & Marketing positions at Cierra, Inc. and Vascular Architects, as well as a variety of roles at Guidant, which was acquired by Abbott Vascular. Prior to Guidant, Mr. Salkeld was a Manager at Ernst & Young, LLP. Mr. Salkeld holds a BS in Commerce and an MBA from Santa Clara University.
Mr. Sancheti has been in operations leadership positions for over 15 years and has over 30 years of manufacturing, supply chain, engineering and operations experience in medical devices including vascular implants, catheters, RF ablation, respiratory assist devices and Robotic Assisted Surgery. Prior to joining PROCEPT BioRobotics, he served as VP, Manufacturing Operations at Intuitive Surgical, among other leadership positions he held there. Previously, Mr. Sancheti held VP Operations roles at Altura Medical, Ceterix Orthopedics, Breathe Technologies and VNUS Medical Technologies. He holds a Bachelor of Science in Mechanical Engineering from the Birla Institute of Technology and Science in India, and a Master of Science in Manufacturing Engineering from the University of Massachusetts.
Mr. Templin has over 15 years of experience in clinical research, engineering, and market development, primarily within the medical device industry. Most recently, he served as the VP of Clinical Research, Engineering, and Therapy Development for CardioKinetix. Prior to CardioKinetix, Mr. Templin was the Global Clinical Program Director for Abbott Vascular. He also led the landmark vulnerable plaque natural history study, PROSPECT. Prior to that role, Mr. Templin held engineering roles with GE Aircraft Engines and Guidant, and then clinical positions with Guidant (that was later acquired by Abbott). Mr. Templin holds a BS in Mechanical Engineering and minor in Economics from Rose-Hulman Institute of Technology and an MBA from Duke.
Ms. Vittal has 20 years of experience in People, Culture and Engagement with a career spanning medical device, fin-tech and high-tech industries. Prior to joining PROCEPT BioRobotics, she was VP, HR at Varian Medical Systems, a world leader in radiotherapy and cancer care, and previously held HR leadership roles at PayPal and CA Technologies. She has experience in building business-driven people programs and high-performing cultures in rapid change environments and has led initiatives in HR business partnership, talent management, organization development and total rewards. Ms. Vittal has a Bachelor of Arts (Honors) degree in Economics from Delhi University, India and a Master of Business Administration from Management Development Institute, Gurgaon, India.
Dr. Zadno has served as PROCEPT BioRobotics President and Chief Executive Officer and a member of the board of directors since February 2020. Prior to joining PROCEPT BioRobotics Dr. Zadno served as President and Chief Executive Officer of Avedro, Inc., an ophthalmology company that developed a proprietary Corneal Remodeling Platform Technology. During his time at Avedro, Inc. from September 2016 to November 2020, he led the company through an IPO and rapid commercialization, and ultimately an acquisition by Glaukos; he also served as a member of the board of directors at Avedro. Prior to Avedro, Dr. Zadno served as Innovation Advisor and Venture Partner at InterWest Partners, a venture capital firm, from January 2012 to January 2018. Dr. Zadno has also served on the boards of directors of Invuity, Inc. from January 2013 to June 2017, where he was a member of the audit committee, and Carbylan Therapeutics, Inc. from June 2013 to November 2016, where he was a member of the audit committee. Dr. Zadno also served on the Board of a number of additional private companies. Dr. Zadno also co-founded PercuSurge, a maker of distal protection devices used in treating occluded carotid arteries and saphenous vein grafts, which was acquired by Medtronic. Dr. Zadno received both a Ph.D. and an M.Sc. in Mechanical Properties of Materials from École Nationale Supérieure des Mines de Paris.
Dr. Moll is the founder, Chairman and CEO of Auris Surgical Robotics. Prior to Auris he was co-founder of Hansen Medical, Restoration Robotics and founder and first CEO of Intuitive Surgical, the world leader in surgical robotics, and a major player in urology. Dr. Moll was a co-founder of Origin Medsystems, and served as the Medical Director of Guidant's Surgical Device Division. Early in his career he founded Endotherapeutics, a pioneering company in laparoscopic surgical technology.
Dr. Moll holds a B.A. degree from the University of California at Berkeley, an M.S. degree in management from Stanford University, and an M.D. degree from the University of Washington.
Dr. Perkins is an internationally known ear surgeon, the founder of the California Ear Institute at Stanford and a successful serial medical device entrepreneur. He is the founder of three public companies: Collagen, Laserscope, and ReSound, and was chairman of the latter two. Dr. Perkins is or was founder or co-founder and chairman of Cohesion, Novacept, Pulmonx, Sound ID, Surgrx, Define, Minerva, Iogyn and Soundhawk.
Dr. Perkins received the Phoenix Hall of Fame Innovation Award and the Lifetime Achievement Award from Medical Futures, a British organization that fosters innovation in medicine. He is a graduate of the Indiana University School of Medicine where he recently received the Distinguished Medical Alumnus Award. Dr. Perkins is a Clinical Professor of Surgery at Stanford and holds over 40 patents.
Mr. Desai is a partner at CPMG, Inc. CPMG is an investment firm that employs a concentrated, value-oriented approach to investing in publicly traded and private operating companies. Prior to joining CPMG’s predecessor, Cardinal Investment Company, Mr. Desai worked as an analyst at WhiteHorse Capital Partners, L.P. He currently serves on the Board of Directors of PROCEPT BioRobotics Corporation, Theatro Labs, Inc., ESN Venture Holdings LLC, Lifeblue Incorporated, and Travel Research Advisors LLC. Mr. Desai holds a B.S. and an M.B.A. from The Wharton School at the University of Pennsylvania.
Ms. Dodrill has served healthcare and technology companies for more than 20 years and is currently the President of Global Surgical Solutions at Hillrom Holdings, Inc. ("Hillrom"). At Hillrom, she has been responsible for achieving enhanced operational effectiveness, market expansion and market share growth. Prior roles at Hillrom include Vice President and General Manager, US Surgical Division, Vice President and General Manager of Trumpf Medical Surgical Solutions NA and Area Vice President & General Manager. Earlier in her career, she served as a Vice President, Commercial Operations at DynaVox, and prior to that was a Regional Vice President at GE Healthcare. Ms. Dodrill holds a Bachelor of Science in Biomedical Engineering from Johns Hopkins University and completed a fellowship in Physiology at Wake Forest University.
Mr. Wood is a Portfolio Manager and Research Analyst for Oechsle International Advisors in London where he is responsible for medical technology investments globally. Prior to this current position, he was with Freeman & Company, a boutique M&A advisory firm focused on the financial services industry. Earlier in his career Mr. Wood was actively involved as an investor, asset gatherer and business development executive for early stage companies in financial services and medical technology sectors.
Mr. Wood holds a B.A. from the University of Delaware and an MBA in Finance and Entrepreneurship from the F.W. Olin Graduate of Business at Babson College.
Mr. Harris most recently served as the Chief Financial Officer of MyoKardia, Inc., a clinical-stage biopharmaceutical company discovering and developing therapies for the treatment of serious cardiovascular diseases. MyoKardia was acquired in November 2020 by Bristol Myers Squibb for $13.1 billion. Prior to joining MyoKardia, Mr. Harris served as Chief Financial Officer of Zeltiq Aesthetics, Inc., until that company’s acquisition by Allergan plc. Prior to Zeltiq, Mr. Harris served as Chief Financial Officer at Thoratec Corporation, until that company’s acquisition by St. Jude Medical, Inc. Prior to joining Thoratec, Mr. Harris worked at JPMorgan Chase & Co. for over a decade in several capacities, including as a Vice President in the firm's Healthcare Investment Banking and Equity Research departments. Mr. Harris holds a Bachelor of Arts in Physics and Economics from the University of North Carolina at Chapel Hill, where he studied as a Morehead-Cain Scholar.
Dr. Krummel is the Surgeon-in-Chief at Lucile Packard Children’s Hospital and Chairman of the Surgery Department at the Stanford University School of Medicine, He is the founder of the Surgical Innovation Program at Stanford, and Co-Director of the Stanford Biodesign Program which teaches innovation and implementation of new surgical technologies. The program has spawned 35 start-ups which have received more than $300 million in follow-on financing.
Dr. Krummel has lectured throughout the world and is author or co-author of over 300 publications, chapters, abstracts and books. He is on the board of the Fogarty Innovation Institute and has served on the board of directors or scientific advisory boards of 15 medical device start-ups.
Careers & Culture
PROCEPT BioRobotics is transforming patient care by pioneering surgical robotics in the field of urology.
- We believe in teamwork, trust, respect, collaboration and a can-do attitude.
- We encourage out-of-the-box thinking and challenging the status quo.
- We know how to work hard and have fun both in the office and outside.
We Invest in Your Wellbeing
As an organization, one of our top priorities is to maintain the health and wellbeing of our employees and their families. To achieve this goal, we offer exciting and comprehensive programs with a variety of options to best meet your needs.
Here are some of the Perks and Benefits that PROCEPT offers:
HEALTH
- Medical
- Dental
- Vision
- FSA
- Wellness programs
- Employee assistance programs
FINANCIAL
- 401k retirement plan
- Stock options
- Long-term disability insurance
- Travel accident insurance on business travel
- Life insurance
- Short Term Disability Insurance
- Annual Bonus Program
LIFESTYLE
- On-site gym
- Commuter discounts
- Student loan discounts
- Pet insurance discounts
- Free snacks and drinks
- Ping pong in the office
- Travel Discounts
- Paid Parental Leave
- Vacation/ Paid Time Off
SOCIAL
- Team building events
- BBQs
- Ice cream socials
- Happy hour gatherings
…and much more
Employee Spotlight
Joined PROCEPT BioRobotics in February 2020
"Surgical robotics has always been a groundbreaking technology but the team here at PROCEPT BioRobotics has taken the concept to a whole new level with our autonomous surgical robot. I also get to work alongside some of the most talented people I have ever met – from marketers to engineers to astronomy buffs and DJs, you're never too far from an interesting conversation. All in all, it's very satisfying to be part of such a dedicated team who not only create great outcomes for our patients but who also provide very unique opportunities for anyone looking to break new ground in their careers."
Joined PROCEPT BioRobotics in October 2018
"The reason I joined PROCEPT BioRobotics was because I knew that I wanted to continue my career in the medical device industry. Initially, when I learned about how the robot worked, I automatically liked the idea that water was being used to improve a person’s quality of life."
"The best part about working at PROCEPT BioRobotics is how collaborative we are as a company. Everyone has different backgrounds and experiences which really helps when trying to tackle projects or even day to day workloads. If I have a question, I’m not afraid to ask for help because I know that someone will be able to help me. There’s no such thing as a silly question at PROCEPT BioRobotics."
"At the end of the day, the most important thing is making sure that the person who receives care from this product has the best outcome and no longer has to suffer from the side effects of BPH. There are definitely long work days, but the hard work really pays off, especially as we get to hear from patients who say how much their lives have improved."
Joined PROCEPT BioRobotics in August 2017
"Working for PROCEPT BioRobotics has been a rewarding experience for me. The accumulated knowledge throughout my years in the industry and the skills I've learned have all been utilized here. I also had the opportunity to witness explosive growth of the company, which was exhilarating. A lot has changed since my first year at PROCEPT BioRobotics but I can only say that greater things are on the horizon. We have a committed CEO who is solidifying what it means to be PROCEPT BioRobotics and I am excited!"
"Now that we're a little bit more established, what continues to attract me is the potential growth of this company. I believe in the people here that are working tirelessly to ensure that Aquablation is the treatment of choice for BPH."
"There are plenty of opportunities for you at PROCEPT if you're flexible and open. Prepare to stretch yourself and you will gain the experience you will need for your next endeavor."
Joined PROCEPT BioRobotics in February 2020
"Surgical robotics has always been a groundbreaking technology but the team here at PROCEPT BioRobotics has taken the concept to a whole new level with our autonomous surgical robot. I also get to work alongside some of the most talented people I have ever met – from marketers to engineers to astronomy buffs and DJs, you're never too far from an interesting conversation. All in all, it's very satisfying to be part of such a dedicated team who not only create great outcomes for our patients but who also provide very unique opportunities for anyone looking to break new ground in their careers."
Joined PROCEPT BioRobotics in October 2018
"The reason I joined PROCEPT BioRobotics was because I knew that I wanted to continue my career in the medical device industry. Initially, when I learned about how the robot worked, I automatically liked the idea that water was being used to improve a person’s quality of life."
"The best part about working at PROCEPT BioRobotics is how collaborative we are as a company. Everyone has different backgrounds and experiences which really helps when trying to tackle projects or even day to day workloads. If I have a question, I’m not afraid to ask for help because I know that someone will be able to help me. There’s no such thing as a silly question at PROCEPT BioRobotics."
"At the end of the day, the most important thing is making sure that the person who receives care from this product has the best outcome and no longer has to suffer from the side effects of BPH. There are definitely long work days, but the hard work really pays off, especially as we get to hear from patients who say how much their lives have improved."
Joined PROCEPT BioRobotics in August 2017
"Working for PROCEPT BioRobotics has been a rewarding experience for me. The accumulated knowledge throughout my years in the industry and the skills I've learned have all been utilized here. I also had the opportunity to witness explosive growth of the company, which was exhilarating. A lot has changed since my first year at PROCEPT BioRobotics but I can only say that greater things are on the horizon. We have a committed CEO who is solidifying what it means to be PROCEPT BioRobotics and I am excited!"
"Now that we're a little bit more established, what continues to attract me is the potential growth of this company. I believe in the people here that are working tirelessly to ensure that Aquablation is the treatment of choice for BPH."
"There are plenty of opportunities for you at PROCEPT if you're flexible and open. Prepare to stretch yourself and you will gain the experience you will need for your next endeavor."
Contact
Contact
